Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer

Alan R. Penheiter, Troy R. Wegman, Kelly L. Classic, David M Dingli, Claire E. Bender, Stephen J Russell, Stephanie K Carlson

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

OBJECTIVE. We have previously shown the therapeutic efficacy of an engineered oncolytic measles virus expressing the sodium iodide symporter reporter gene (MV-NIS) in mice with human pancreatic cancer xenografts. The goal of this study was to determine the synergy between MV-NIS-induced oncolysis and NIS-mediated 131I radiotherapy in this tumor model. MATERIALS AND METHODS. Subcutaneous human BxPC-3 pancreatic tumors were injected twice with MV-NIS. Viral infection, NIS expression, and intratumoral iodide uptake were quantitated with 123I micro-SPECT/CT. Mice with MV-NIS-infected tumors were treated with 0, 37, or 74 MBq 131I and monitored for tumor progression and survival. Additional studies were performed with stable NIS-expressing tumors (BxPC-3-NIS) treated with 0, 3.7, 18.5, 37, or 74 MBq of 131I. RESULTS. Mice treated with intratumoral MV-NIS exhibited significant tumor growth delay (p < 0.01) and prolonged survival (p = 0.02) compared with untreated mice. Synergy between MV-NIS-induced oncolysis and NIS-mediated 131I ablation was not seen; however, a significant correlation was observed between NIS-mediated intratumoral iodide localization (% ID/g) and peak tumor volume reduction (p = 0.04) with combination MV-NIS and 131I therapy. Stably transduced NIS-expressing BxPC-3 tumors exhibited rapid regression with ≥ 18.5 MBq 131I. CONCLUSION. Delivery of 131I radiotherapy to NIS-expressing tumors can be optimized using micro-SPECT/CT imaging guidance. Significant hurdles exist for NIS as a therapeutic gene for combined radiovirotherapy in this human pancreatic cancer model. The lack of synergy observed with MV-NIS and 131I in this model was not due to a lack of radiosensitivity but rather to a nonuniform intratumoral distribution of MV-NIS infection.

Original languageEnglish (US)
Pages (from-to)341-349
Number of pages9
JournalAmerican Journal of Roentgenology
Volume195
Issue number2
DOIs
StatePublished - 2010

Fingerprint

Pancreatic Neoplasms
Neoplasms
Iodides
Radiotherapy
Oncolytic Viruses
Measles virus
Survival
sodium-iodide symporter
Radiation Tolerance
Virus Diseases
Tumor Burden
Reporter Genes
Heterografts
Therapeutics
Growth
Infection
Genes

Keywords

  • I
  • hNIS
  • Measles virus
  • Pancreatic cancer
  • Sodium iodide symporter (NIS)

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. / Penheiter, Alan R.; Wegman, Troy R.; Classic, Kelly L.; Dingli, David M; Bender, Claire E.; Russell, Stephen J; Carlson, Stephanie K.

In: American Journal of Roentgenology, Vol. 195, No. 2, 2010, p. 341-349.

Research output: Contribution to journalArticle

Penheiter, Alan R. ; Wegman, Troy R. ; Classic, Kelly L. ; Dingli, David M ; Bender, Claire E. ; Russell, Stephen J ; Carlson, Stephanie K. / Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. In: American Journal of Roentgenology. 2010 ; Vol. 195, No. 2. pp. 341-349.
@article{dbe18ebfa81446b287e37ed848757d5f,
title = "Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer",
abstract = "OBJECTIVE. We have previously shown the therapeutic efficacy of an engineered oncolytic measles virus expressing the sodium iodide symporter reporter gene (MV-NIS) in mice with human pancreatic cancer xenografts. The goal of this study was to determine the synergy between MV-NIS-induced oncolysis and NIS-mediated 131I radiotherapy in this tumor model. MATERIALS AND METHODS. Subcutaneous human BxPC-3 pancreatic tumors were injected twice with MV-NIS. Viral infection, NIS expression, and intratumoral iodide uptake were quantitated with 123I micro-SPECT/CT. Mice with MV-NIS-infected tumors were treated with 0, 37, or 74 MBq 131I and monitored for tumor progression and survival. Additional studies were performed with stable NIS-expressing tumors (BxPC-3-NIS) treated with 0, 3.7, 18.5, 37, or 74 MBq of 131I. RESULTS. Mice treated with intratumoral MV-NIS exhibited significant tumor growth delay (p < 0.01) and prolonged survival (p = 0.02) compared with untreated mice. Synergy between MV-NIS-induced oncolysis and NIS-mediated 131I ablation was not seen; however, a significant correlation was observed between NIS-mediated intratumoral iodide localization ({\%} ID/g) and peak tumor volume reduction (p = 0.04) with combination MV-NIS and 131I therapy. Stably transduced NIS-expressing BxPC-3 tumors exhibited rapid regression with ≥ 18.5 MBq 131I. CONCLUSION. Delivery of 131I radiotherapy to NIS-expressing tumors can be optimized using micro-SPECT/CT imaging guidance. Significant hurdles exist for NIS as a therapeutic gene for combined radiovirotherapy in this human pancreatic cancer model. The lack of synergy observed with MV-NIS and 131I in this model was not due to a lack of radiosensitivity but rather to a nonuniform intratumoral distribution of MV-NIS infection.",
keywords = "I, hNIS, Measles virus, Pancreatic cancer, Sodium iodide symporter (NIS)",
author = "Penheiter, {Alan R.} and Wegman, {Troy R.} and Classic, {Kelly L.} and Dingli, {David M} and Bender, {Claire E.} and Russell, {Stephen J} and Carlson, {Stephanie K}",
year = "2010",
doi = "10.2214/AJR.09.3672",
language = "English (US)",
volume = "195",
pages = "341--349",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "2",

}

TY - JOUR

T1 - Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer

AU - Penheiter, Alan R.

AU - Wegman, Troy R.

AU - Classic, Kelly L.

AU - Dingli, David M

AU - Bender, Claire E.

AU - Russell, Stephen J

AU - Carlson, Stephanie K

PY - 2010

Y1 - 2010

N2 - OBJECTIVE. We have previously shown the therapeutic efficacy of an engineered oncolytic measles virus expressing the sodium iodide symporter reporter gene (MV-NIS) in mice with human pancreatic cancer xenografts. The goal of this study was to determine the synergy between MV-NIS-induced oncolysis and NIS-mediated 131I radiotherapy in this tumor model. MATERIALS AND METHODS. Subcutaneous human BxPC-3 pancreatic tumors were injected twice with MV-NIS. Viral infection, NIS expression, and intratumoral iodide uptake were quantitated with 123I micro-SPECT/CT. Mice with MV-NIS-infected tumors were treated with 0, 37, or 74 MBq 131I and monitored for tumor progression and survival. Additional studies were performed with stable NIS-expressing tumors (BxPC-3-NIS) treated with 0, 3.7, 18.5, 37, or 74 MBq of 131I. RESULTS. Mice treated with intratumoral MV-NIS exhibited significant tumor growth delay (p < 0.01) and prolonged survival (p = 0.02) compared with untreated mice. Synergy between MV-NIS-induced oncolysis and NIS-mediated 131I ablation was not seen; however, a significant correlation was observed between NIS-mediated intratumoral iodide localization (% ID/g) and peak tumor volume reduction (p = 0.04) with combination MV-NIS and 131I therapy. Stably transduced NIS-expressing BxPC-3 tumors exhibited rapid regression with ≥ 18.5 MBq 131I. CONCLUSION. Delivery of 131I radiotherapy to NIS-expressing tumors can be optimized using micro-SPECT/CT imaging guidance. Significant hurdles exist for NIS as a therapeutic gene for combined radiovirotherapy in this human pancreatic cancer model. The lack of synergy observed with MV-NIS and 131I in this model was not due to a lack of radiosensitivity but rather to a nonuniform intratumoral distribution of MV-NIS infection.

AB - OBJECTIVE. We have previously shown the therapeutic efficacy of an engineered oncolytic measles virus expressing the sodium iodide symporter reporter gene (MV-NIS) in mice with human pancreatic cancer xenografts. The goal of this study was to determine the synergy between MV-NIS-induced oncolysis and NIS-mediated 131I radiotherapy in this tumor model. MATERIALS AND METHODS. Subcutaneous human BxPC-3 pancreatic tumors were injected twice with MV-NIS. Viral infection, NIS expression, and intratumoral iodide uptake were quantitated with 123I micro-SPECT/CT. Mice with MV-NIS-infected tumors were treated with 0, 37, or 74 MBq 131I and monitored for tumor progression and survival. Additional studies were performed with stable NIS-expressing tumors (BxPC-3-NIS) treated with 0, 3.7, 18.5, 37, or 74 MBq of 131I. RESULTS. Mice treated with intratumoral MV-NIS exhibited significant tumor growth delay (p < 0.01) and prolonged survival (p = 0.02) compared with untreated mice. Synergy between MV-NIS-induced oncolysis and NIS-mediated 131I ablation was not seen; however, a significant correlation was observed between NIS-mediated intratumoral iodide localization (% ID/g) and peak tumor volume reduction (p = 0.04) with combination MV-NIS and 131I therapy. Stably transduced NIS-expressing BxPC-3 tumors exhibited rapid regression with ≥ 18.5 MBq 131I. CONCLUSION. Delivery of 131I radiotherapy to NIS-expressing tumors can be optimized using micro-SPECT/CT imaging guidance. Significant hurdles exist for NIS as a therapeutic gene for combined radiovirotherapy in this human pancreatic cancer model. The lack of synergy observed with MV-NIS and 131I in this model was not due to a lack of radiosensitivity but rather to a nonuniform intratumoral distribution of MV-NIS infection.

KW - I

KW - hNIS

KW - Measles virus

KW - Pancreatic cancer

KW - Sodium iodide symporter (NIS)

UR - http://www.scopus.com/inward/record.url?scp=77955591776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955591776&partnerID=8YFLogxK

U2 - 10.2214/AJR.09.3672

DO - 10.2214/AJR.09.3672

M3 - Article

C2 - 20651188

AN - SCOPUS:77955591776

VL - 195

SP - 341

EP - 349

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 2

ER -